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Prescribing of drugs is a challenge, particularly in older people who are sensitive to drug effects and often suffer from multiple morbidities. In fact, it is well-known that suboptimal pharmacotherapy is common in older people, such as treatment with inappropriate drugs or dosages, and/or omissions of drugs which the patient would probably benefit from \[[@CR1]--[@CR3]\].

In order to improve the quality of drug treatment, explicit criteria may serve as tools to identify potential problems, as potentially inappropriate medications (PIMs) and potential prescription omissions (PPOs). Some criteria can be applied on the drug list alone, whereas others require clinical information such as diagnoses and laboratory parameters \[[@CR4]--[@CR7]\]. The screening tool of older persons' potentially inappropriate prescriptions (STOPP) and the screening tool to alert to right treatment (START) criteria belong to the ones requiring clinical information \[[@CR8]\]. These criteria have been used in several studies describing drug treatment quality \[[@CR9], [@CR10]\]. The original version was developed to be applied in the clinical situation by the attending physician, and provide 65 criteria for potentially inappropriate drugs and 22 criteria for potentially missing drugs, respectively. An updated, more extensive, version has been published \[[@CR11]\].

To apply the first version of the STOPP/START criteria has been estimated to require an additional 3 min for the physician-patient consultation \[[@CR12]\]. However, even though the additional minutes required may be few under optimal conditions, constraints of time may be an obstacle for implementation \[[@CR13]\]. Indeed, as information on medical conditions and medication history within an electronic patient record is not always easily retrieved \[[@CR14]\], systematically checking an extensive set of criteria may be time-consuming.

To facilitate for physicians to take advantage of criteria in clinical practice, the first step may be to minimize the extra time needed for the application. This can be achieved by focusing on frequently occurring criteria, easy to assess given available information in the medical records, and often of clinical relevance. However, although experts have often assessed available criteria sets for relevance, credibility, and acceptability at the general level \[[@CR15], [@CR16]\], less is known about the extent of their clinical relevance at the individual level.

In addition to easily applicable criteria requiring a minimum of time, physicians may want to know which patients would be most worthwhile to assess a bit further. Indeed, potentially suboptimal drug treatment has been associated with age, sex, and number of drugs \[[@CR17]\]. However, less is known on patient characteristics associated with clinically relevant prescribing problems, a question of superior interest to the attending physician.

The aim of this study was to investigate the clinical relevance of PIMs and PPOs identified by the STOPP/START criteria, and to identify predictors for clinically relevant PIMs/PPOs.
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The present study was performed within a cohort of older hip fracture patients, consecutively recruited to a randomized controlled study in the departments of orthopedics, geriatrics, and medicine at Sahlgrenska University Hospital in 2009 \[[@CR18]\]. Inclusion criteria in the original study were patients, ≥65 years of age, who had undergone surgery for a hip fracture at Sahlgrenska University Hospital, were residing in the Gothenburg area, and provided informed consent. In all, 200 out of 253 patients undergoing hip fracture surgery during the inclusion period were included in the original study; 23 declined participation, 14 did not fulfill the other inclusion criteria, 10 were deceased before inclusion, and six were excluded because of other reasons.

In the original study, the medication list at study entry (admission to hospital) was determined. When a patient could not report satisfactorily on his/her medications, the Swedish Register of Dispensed Drugs (Läkemedelsförteckningen) was consulted, holding information available in clinical practice for the attending physician on prescribed drugs purchased from any Swedish pharmacy during the preceding 15 months. Drugs used regularly and as needed were included. Drugs for external use were included only if having potential systemic effects. Thus, topical medications, tear substitutes, and dental fluoride preparations were excluded.

In the present study, the STOPP and START criteria were applied on the medication list determined in the original study, identifying PIMs and PPOs. The clinical relevance of each PIM/PPO was assessed at the individual level. If the expected benefit of a particular medication was judged to outweigh the potential harm, such as an antipsychotic drug in a patient with schizophrenia, the PIM was assessed as not clinically relevant. Similarly, if there was a clinical reason not to treat the patient with the drug, such as an adverse drug reaction or a contraindication, the PPO was assessed as not clinically relevant. When the information available was not sufficient to determine the clinical relevance, the PIM/PPO was categorized as not assessable.

The assessments were independently performed by one general practitioner and one geriatrician in 2012--2013. They were based on (1) medical records from both hospital and primary care and (2) previously collected data including information on risk of falls, cognition, residence, and glomerular filtration rate. The latter, estimated with the Cockcroft-Gault equation, was dichotomized as either ≥50 or \<50 ml/min to fit the STOPP and START criteria. In a final consensus discussion, the two specialist physicians reached agreement on identified PIMs/PPOs, and the clinical relevance of these.
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All statistical analyses were performed with SPSS (IBM SPSS Statistics for Windows, Version 17.0, Armonk, NY). We used the Mann Whitney and the chi-square tests for comparisons of characteristics between patients with and without ≥1 clinically relevant PIMs/PPOs, and 95% confidence intervals (CI) were calculated for proportions. Kappa statistics was used to assess inter-rater agreement. Logistic regression was performed to obtain odds ratios (and 95% CI) for ≥1 PIMs/PPOs, as well as ≥1 clinically relevant PIMs/PPOs. In the main analysis, due to the fact that we wanted to identify quickly adoptable criteria, we chose to categorize not assessable PIMs/PPOs as not clinically relevant. A sensitivity analysis was performed where not assessable PIMs/PPOs were categorized as clinically relevant. Covariates included in the analysis were age, sex, cognition (defined as impaired or not), residence (defined as nursing home or not; nursing home residence reflecting that the patient needed help with daily living activities), multidose drug dispensing (defined as having ≥1 drugs prescribed via this system; associated with quality of drug treatment in prior studies \[[@CR19]--[@CR21]\]), and number of drugs (a proxy for burden of disease \[[@CR22]\]).
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Characteristics of patients by results on STOPP/START criteria are presented in Table [1](#Tab1){ref-type="table"}. Summarized, the patients had a mean age of 84.5 years, ranging from 65 to 98 years, and 133 (67%) were women. The mean number of drugs in the medication list was 7.2 ± 3.9 (range 0--21). Multidose drug dispensing, was consistently more common in patients with PIMs/PPOs, irrespective of their being clinically relevant or not. These patients also had more drugs in their medication list.Table 1Characteristics of patients according to presence of ≥1 potentially inappropriate medications (PIMs) and/or ≥1 potential prescription omissions (PPOs), identified by the STOPP and START criteria, respectively≥1 PIMs/PPOs≥1 clinically relevant PIMs/PPOsYesNoYesNo*n* = 170*n* = 30*P* value*n* = 141*n* = 59*P* valueAgeMean ± SD85.1 ± 6.781.1 ± 8.384.8 ± 6.883.7 ± 7.6Median (range)85 (65--98)80 (65--98)0.00985 (65--98)85 (65--98)0.37Female sex112 (66)21 (70)0.6692 (65)41 (69)0.56Multidose drug dispensing97 (57)3 (10)\<0.000186 (61)14 (24)\<0.0001Impaired cognition84 (49)6 (20)0.00369 (49)21 (36)0.084Residing in nursing home56 (33)4 (13)0.03147 (33)13 (22)0.11Number of drugsMean ± SD7.7 ± 3.74.1 ± 3.78.2 ± 3.64.8 ± 3.6Median (range)7 (0--21)3 (0--15)\<0.00018 (2--21)4 (0--15)\<0.0001Values are presented as number of patients (percentage) if not stated otherwise*SD* standard deviation, *STOPP* screening tool of older person's potentially inappropriate prescription, *START* screening tool to alert to right treatment

A total of 555 PIMs/PPOs were identified in 170 (85%) patients; 298 (54%) of which, in 141 (71%) patients, were assessed as clinically relevant. The inter-rater agreement was moderate (kappa 0.52). A greater proportion of PIMs than PPOs was clinically relevant: 217 in 305 (71% (95% CI: 66%; 76%)) vs. 81 in 250 (32% (27%; 38%)). The median number of clinically relevant PIMs and PPOs per patient was 1 (mean 1.09, range 0--6) and 0 (mean 0.41, range 0--3), respectively.

In all, 160 (29%) PIMs/PPOs were not assessable. A greater proportion of PPOs than PIMs could not be determined with available information: 94 (38% (32%; 44%)) vs. 66 (22% (17%; 27%).

For six (9.2%) out of 65 STOPP and two (9.1%) out of 22 START criteria, ≥10 (5%) patients had a clinically relevant PIM and PPO, respectively (Table [2](#Tab2){ref-type="table"}). For 37 (57%) STOPP and 17 (77%) START criteria, ≥1 (≥0.5%) patients had a clinically relevant PIM and PPO, respectively.Table 2Potentially inappropriate medications (PIMs) and potential prescription omissions (PPOs), identified by the STOPP and START criteria, respectively, identified in ≥5% of the study cohort (*n* ≥ 10)DescriptionPIM/PPO\*Clinically relevant PIM/PPO\*\*Not clinically relevant PIM/PPO\*\*Not assessable PIM/PPO\*\*Benzodiazepines in those prone to fallsSTOPP76 (38)47 (62)0 (0)29 (38)Osteoporosis and no calcium and vitamin D supplementationSTART61 (31)10 (16)4 (7)47 (77)Chronic atrial fibrillation without warfarinSTART29 (155)7 (24)14 (48)8 (28)Aspirin with no history of coronary, cerebral or peripheral arterial symptoms, or occlusive arterial eventSTOPP27 (14)13 (48)12 (44)2 (7.4)Aspirin at dose \>150 mg daySTOPP24 (12)23 (96)1 (4)0 (0)Loop diuretic for dependent ankle edema only i.e., no clinical signs of heart failureSTOPP24 (12)20 (83)0 (0)4 (17)Atherosclerotic disease with sinus rhythm without aspirin or clopidogrelSTART21 (11)9 (43)8 (38)4 (19)Chronic heart failure without ACE inhibitorSTART20 (10)5 (25)10 (50)5 (25)Diabetes mellitus and ≥1 coexisting major cardiovascular risk factor without a statinSTART19 (9.5)4 (21)11 (58)4 (21)Neuroleptic drugs in those prone to fallsSTOPP17 (8.5)11 (65)0 (0)6 (35)Chronic stable angina and no beta-blockerSTART17 (8.5)10 (59)3 (16)4 (24)Vascular disease and a life expectancy of \>5 years without a statinSTART16 (8)9 (56)2 (13)5 (31)Long-term opiates in those with recurrent fallsSTOPP16 (8)9 (56)0 (0)7 (44)Prior acute myocardial infarction and no ACE inhibitorSTART15 (7.5)3 (20)7 (44)5 (33)Long-term long-acting benzodiazepinesSTOPP13 (6.5)13 (100)0 (0)0 (0)Vasodilator drugs known to cause hypotension in those with persistent postural hypotensionSTOPP11 (5.5)9 (82)1 (9)1 (9.1)Diabetes mellitus and ≥1 coexisting major cardiovascular risk factor without antiplatelet therapySTART11 (5.5)2 (18)7 (64)2 (18)Maintained oral corticosteroid therapy without bisphosphonatesSTART10 (5)5 (50)3 (30)2 (20)Values are presented as number of patients (\*percentage of all patients; \*\*percentage of patients with PIM/PPO)*ACE* angiotensin converting enzyme, *STOPP* screening tool of older person's potentially inappropriate prescription, *START* screening tool to alert to right treatment

The most frequently occurring PIMs were benzodiazepines in those prone to falls, and aspirin either without cardiovascular disease or at a dose \>150 mg/day. The PIMs long-acting benzodiazepines and aspirin at a dose \>150 mg/day were clinically relevant in all but one patient. As for loop diuretics without clinical signs of heart failure and for bensodiazepines, no PIM was assessed as not clinically relevant. Although not frequently occurring (5.5%), the PIM vasodilator drugs in patients with postural hypotension were clinically relevant in 82% of the cases. Among patients prone to falls, the clinical relevance of the frequent PIMs concerning benzodiazepines, neuroleptics, and opiates could not be determined in 35--44% of the cases.

The most frequently occurring PPOs were osteoporosis without calcium and vitamin D supplementation, and chronic atrial fibrillation without warfarin; 16% and 24% of which, respectively, were assessed as clinically relevant. Clinical relevance could not be determined in 77% of the cases for calcium and vitamin D. Among frequent PPOs in patients with cardiovascular disease, the clinical relevance could not be determined in 21--33% of the cases when it came to treatment with angiotensin converting enzyme inhibitors, warfarin, beta-blockers, or statins.

In the main analysis, as well as the sensitivity analysis, the odds for ≥1 clinically relevant PIMs/PPOs were greater for patients with multidose drug dispensing and increased by the number of drugs in the medication list (Table [3](#Tab3){ref-type="table"}). Age, sex, cognition, and nursing home residence was not statistically significantly associated with suboptimal drug treatment.Table 3Odds ratios (95% confidence interval) for ≥1 potentially inappropriate medications (PIMs) and/or ≥1 potential prescription omissions (PPOs), identified by the STOPP and START criteria, respectively, according to characteristics of the patient≥1 PIMs/PPOs according to≥1 clinically relevant PIMs/PPOs according toSTOPP/STARTSTOPPSTARTSTOPP/STARTSTOPPSTARTAge1.05 (0.98; 1.12)1.02 (0.97; 1.08)1.02 (0.97; 10.7)0.99 (0.93; 1.04) *1.04 (0.98; 1.10)*1.01 (0.96; 1.06) *1.04 (0.98; 1.10)*0.98 (0.93; 1.03) *1.03 (0.98; 1.08)*Sex0.73 (0.28; 1.92)0.59 (0.27; 1.29)0.81 (0.42; 1.58)0.80 (0.37; 1.70) *0.72 (0.30; 1.73)*1.24 (0.62; 2.46) *0.66 (0.31; 1.42)*1.05 (0.55; 2.01) *0.97 (0.52; 1.80)*MDD[10.6 (1.60; 70.1)]{.ul}2.55 (0.87; 7.48)2.23 (0.89; 5.60)[7.95 (2.35; 26.9)]{.ul} *[6.96 (1.50; 32.3)]{.ul}*[2.90 (1.14; 7.38)]{.ul} *2.50 (0.88; 7.09)*1.82 (0.77; 4.30) *2.01 (0.86; 4.72)*Impaired cognition1.28 (0.37; 4.40)0.95 (0.37; 2.42)1.52 (0.68; 3.39)0.54 (0.20; 1.45) *1.13 (0.38; 3.38)*0.69 (0.30; 1.59) *0.94 (0.38; 2.34)*1.03 (0.48; 2.24) *1.23 (0.59; 2.58)*Nursing home resident0.29 (0.05; 1.77)1.31 (0.44; 3.99)0.46 (0.19; 1.16)0.52 (0.17; 1.63) *0.22 (0.05; 1.00)*1.17 (0.47; 2.89) *0.95 (0.33; 2.72)*0.60 (0.27; 1.35) *[0.34 (0.15; 0.76)]{.ul}*Number of drugs[1.28 (1.11; 1.48)1.35 (1.19; 1.53)]{.ul}1.08 (0.99; 1.17)[1.28 (1.14; 1.43)]{.ul} *[1.24 (1.09; 1.40)]{.ul}*[1.27 (1.15; 1.41)]{.ul} *[1.37 (1.21; 1.54)]{.ul}*1.08 (0.99; 1.17) *1.03 (0.96; 1.12)*Figures in italics represent results in the sensitivity analysis where not assessable PIMs/PPOs were categorized as clinically relevant. Odds ratios which do not cross the line of unity are underlined*STOPP* screening tool of older person's potentially inappropriate prescription, *START* screening tool to alert to right treatment, *MDD* multi-dose drug dispensing
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Our study shows that, at the overall level, one in two PIMs/PPOs, identified with the STOPP/START criteria, is clinically relevant according to the easily retrievable documentation. PIMs are clinically relevant to a greater extent, and PPOs are more often hard to assess concerning clinical relevance. The prevalence of over- and undertreatment according to various STOPP and START criteria varies, and for only six out of 65 STOPP and two out of 22 START criteria, a clinically relevant PIM and PPO, respectively, was identified in more than 5% of the patients.

In the scientific literature, there are numerous publications on the prevalence of suboptimal drug treatment according to various criteria \[[@CR9]\]. In a review focusing specifically on the prevalence of STOPP/START criteria, the figures in various populations varied between 21 and 79% \[[@CR10]\]. Our results are in the same range as these studies. Nevertheless, our finding that only half of the identified PIMs/PPOs were clearly clinically relevant at the individual level suggests that estimated prevalences of suboptimal drug treatment based on these criteria alone may need to be interpreted with caution.

As a first step to improve the quality of drug treatment in older people, without taking too much time and effort, physicians may want to consider to stop treatment with long-acting benzodiazepines and aspirin at doses \>150 mg/day. Indeed, in this study, this kind of treatment could be subject to change in almost 100% of the cases. Similarly, the use of loop diuretics without clinical signs of heart failure and vasodilator drugs in patients with postural hypotension could be worth reconsideration. When it comes to identifying undertreatment and adding drug(s) to the medication list, it may be a successful strategy to start off to assess if a patient with cardiovascular disease would benefit from treatment with an angiotensin converting enzyme inhibitor, warfarin (or other oral anticoagulants), a beta-blocker, or a statin. Indeed, in seven to eight cases out of ten without such treatment, information available in the medical records will suffice to assess the need.

Regarding which patients for physicians to focus upon, those with multidose drug dispensing were to an increased extent subjected to suboptimal treatment. This finding supports previous studies where this system has been associated with fewer changes in drug treatment, and poorer quality of drug treatment \[[@CR19]--[@CR21]\]. Further, for those with many drugs, overtreatment needs to be considered. In fact, the number of drugs may reflect burden of disease \[[@CR22]\], which, in turn, may suggest a greater treatment complexity. Regarding undertreatment, no significant predictor was identified in the main analysis, indicating that such treatment needs to be considered in all cases. Indeed, a previous study has shown that, at ≥2 drugs in the medication list, the number of missing drugs remains stable irrespective of the number of drugs in the medication list \[[@CR23]\]. Interestingly, age and sex were not associated with clinically relevant PIMs/PPOs, although such an association has previously been shown regarding potentially relevant criteria \[[@CR17]\]. Further, no significant association with cognition and nursing home residence was found.

In our study, 71% of identified PIMs and 32% of identified PPOs were considered clinically relevant. These figures are similar to the implementation rate reported in a recent study: 56 and 39% of PIMs and PPOs, respectively \[[@CR24]\]. However, another study reported that 91% of STOPP and 97% of START recommendations were accepted by the attending physician \[[@CR12]\]. The divergence between the results may be explained by the settings of the latter study. In that study, a research physician discussed recommendations based on STOPP/START with the attending medical team. Thus, PIMs/PPOs from the start assessed as not clinically relevant would probably not be discussed at all due to the medical expertise of the intervener, and therefore not captured in the denominator.

The results of this study may contribute to the understanding of the lack of effects for third party medication reviews regarding patient relevant outcomes reflecting the net effect of drug treatment, such as death and hospitalizations \[[@CR25]--[@CR27]\]. In addition to the fact that indicator sets may have a low sensitivity \[[@CR28], [@CR29]\], our study shows that only five in ten identified PIMs/PPOs were clinically relevant, and an additional three were hard to determine concerning clinical relevance given easily available information. The latter finding highlights the importance of a medical assessment of the entire patient as the basis to determine the appropriateness of drug treatment, including the medical history, a physical and/or psychiatric examination, and laboratory tests. Our findings may also explain that only a limited proportion of alerts to drug treatment changes upon third party medication reviews are acted upon \[[@CR30]\].

The most important strengths of this study are that it provides knowledge on the clinical relevance of the STOPP/START criteria, and identifies easily manageable advice to improve drug treatment quality in older people. The results are strengthened by the fact that the underlying assessments of clinical relevance were performed by two specialist physicians with expertise in the relevant area. As could be expected, the inter-rater agreement was moderate, illustrating the subjectivity of clinical judgments and the advantage to involve two assessors.

The fact that we have focused on hip fracture patients may have implications for the generalizability of the results. However, these patients may represent a relevant subgroup of older patients since hip fracture is a common diagnosis in Sweden where every fourth middle-aged woman will sustain a hip fracture during her lifetime, and one out of three hip fracture patients is a man \[[@CR31]\]. Further, suboptimal drug treatment is common in this patient group \[[@CR32]\]. However, the prevalence of suboptimal drug treatment, especially inappropriate drugs related to fall risk, may differ from that found in a general population of older people, and the results may therefore mainly be applicable to hip fracture patients and frail older patients. Another limitation of this study is that the STOPP/START tools, which were used to systemize the specialist assessments, may not capture all kinds of suboptimal drug treatment \[[@CR24]\].

In conclusion, this study illustrates the clinical relevance of the STOPP/START criteria sets, presenting suggestions on which criteria and which patients to focus upon for a physician in constraints of time. Indeed, a medical assessment is the key step when it comes to choosing drug treatment, as all prescribing has to be adapted to the characteristics of the individual patient.

The authors are grateful to Christina Sjöberg (MD, PhD) who collected the data of the patients, as well as Björn Belfrage (MD, general practitioner) and Anders Koldestam MD, (specialist in geriatrics) who performed the drug treatment assessments.

Author's contributions {#FPar1}
======================

S.M. Wallerstedt was responsible for the study concept and design. J. Lönnbro and S.M. Wallerstedt performed the statistical analyses, drafted and revised the manuscript for intellectual content, and approved the final version for submission.

The study complies with the Declaration of Helsinki, and ethics approval was obtained from the Regional Ethical Review Board in Gothenburg.

Conflict of interest {#FPar2}
====================

The authors declare that they have no conflicts of interest.

Funding {#FPar3}
=======

The study was supported by the Swedish Research Council (521-2013-2639) and the Health and Medical Care Committee of the Region Västra Götaland (ALFGBG-428711). The funding sources did not influence the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
